Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/55327
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Malhi, G. | - |
dc.contributor.author | Ng, F. | - |
dc.contributor.author | Berk, M. | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Australian and New Zealand Journal of Psychiatry, 2008; 42(4):346-349 | - |
dc.identifier.issn | 0004-8674 | - |
dc.identifier.issn | 1440-1614 | - |
dc.identifier.uri | http://hdl.handle.net/2440/55327 | - |
dc.description.abstract | Objective: Venlafaxine and mirtazapine in combination are increasingly used in clinical practice to treat treatment-refractory depression. Putative efficacy for this combination of antidepressants, beyond that of monotherapy, stems from their synergistic actions. This paper describes a prospective case series that examined the efficacy of the venlafaxine–mirtazapine combination in the treatment of depressed patients who had failed at least one antidepressant trial. Method: Twenty-two depressed patients with major depression were treated with venlafaxine and mirtazapine in combination for an average of just under 8weeks. Baseline ratings on the 17-item Hamilton Depression Rating Scale (HAM-D17), Montgomery–Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression–Severity Scale (CGI-S) were repeated at end-point, determined by the naturalistic termination of the depressive treatment episode or the discontinuation of the combination treatment due to adverse effects. The length of treatment until end-point was documented for each patient. Descriptive statistics were used on the collated data. Results: At baseline, mean scores were 28.8 (SD=3.8) for HAM-D17, 30.1 (SD=5.8) for MADRS, and 4.5 (SD=0.5) for CGI-S, reflecting a cohort at the moderate to severe end of the spectrum. At end-point, mean absolute scores were 10.2 (SD=4.7) for HAM-D17, 10.8 (SD=4.6) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean change from baseline was 18.6 (SD=6.4) for HAM-D17, 19.3 (SD=6.8) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean duration of treatment was approximately 8weeks, producing a response rate of 81.8% and a remission rate of 27.3%. Only one patient was unable to tolerate the combination although nearly half (10) had significant side-effects during treatment. Conclusion: This study demonstrates relatively high response and remission rates that are encouraging and contribute to the efficacy database for this antidepressant combination. Further studies using randomized controlled designs are needed. | - |
dc.description.statementofresponsibility | Gin S. Malhi, Felicity Ng and Michael Berk | - |
dc.language.iso | en | - |
dc.publisher | Blackwell Publishing Asia | - |
dc.source.uri | http://dx.doi.org/10.1080/00048670701881587 | - |
dc.subject | Humans | - |
dc.subject | Cyclohexanols | - |
dc.subject | Mianserin | - |
dc.subject | Antidepressive Agents, Second-Generation | - |
dc.subject | Antidepressive Agents, Tricyclic | - |
dc.subject | Treatment Outcome | - |
dc.subject | Drug Therapy, Combination | - |
dc.subject | Remission Induction | - |
dc.subject | Severity of Illness Index | - |
dc.subject | Cohort Studies | - |
dc.subject | Prospective Studies | - |
dc.subject | Depressive Disorder | - |
dc.subject | Psychiatric Status Rating Scales | - |
dc.subject | Drug Synergism | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Middle Aged | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.subject | Venlafaxine Hydrochloride | - |
dc.subject | Mirtazapine | - |
dc.title | Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1080/00048670701881587 | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest 5 Psychiatry publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.